Sus Clinicals

Oncopig® Pancreatic Cancer Model

The Oncopig®: A Preclinical Model for Cancer Research

- **The Oncopig® :** A transgenic model that enables precise induction of diverse tumor types in specific tissues or cell types at targeted times.
- Tumors expresses KRAS G12D and TP53 R167H driver mutations, with additional tumor customization possible through CRISPR-based mutation editing.
- **Human-Like Characteristics:** Tumors have remarkably comparable size, anatomy, histology and drug metabolism
- **Comorbidity Models:** Ability to include clinically relevant comorbidities like alcohol induced liver cirrhosis.



Schook, L. B., et al. (2015). Unraveling the Swine Genome: Implications for Human Health. *Annual Review of Animal Biosciences*, 3, 219–244. https://doi.org/10.1146/annurev-animal-022114-110815

100% of Oncopigs with Tumor Formation





Tumors Targetable Via Angiography

Oncopig® Pancreatic Tumor Induction

- **On-Demand Tumor Generation**: CT or laparoscopy-guided pancreas biopsy collection, AdCre incubation, and re-injection results in neoplastic tumors at defined locations within the pancreas.
- **Tumor Formation:** Tumors form in 85% of injection sites and reach a size of 0.5 - 5.1 cm within 1 week.
- **Imaging Capabilities:** Tumors are targetable using CT, MRI, and angiography.

Neoplastic Tumor Masses With Non-Specific Histology



H&E



Cytokeratin



Gross Pathology



Vimentin

- Undifferentiated carcinomas resembling undifferentiated carcinomas of the pancreatobiliary tract in humans.
- Tumors are accompanied by a major inflammatory component.
- Presence of epithelial (cytokeratin) and mesenchymal (vimentin) differentiation.

Reach out for more information!
info@susclinicals.com

Sus Clinicals